Oramed Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Oramed Pharmaceuticals generated cash of -$10,295,000, which is more than the previous year. Cash used in financing activities reached the amount of $51,978,000 last year. Net change in cash is therefore -$31,409,000.
Cash Flow
| 2010 | -1.41M | 901.24K | 0 |
|---|---|---|---|
| 2011 | -1.66M | -1.71M | 3.69M |
| 2012 | -2.30M | 1.76M | 3.48M |
| 2013 | -3.39M | -4.56M | 5.82M |
| 2014 | -4.06M | -13.08M | 16.64M |
| 2016 | 4.65M | -16.01M | 12.04M |
| 2018 | -14.65M | -7.00M | 22.65M |
| 2020 | -12.44M | 4.62M | 23.78M |
| 2021 | -21.18M | -23.76M | 102.89M |
| 2023 | -10.29M | -73.03M | 51.97M |
ORMP Cash Flow Statement (2010 – 2023)
| 2023 | 2021 | 2020 | 2018 | 2016 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 40.46M | 19.29M | 3.32M | 3.96M | 3.21M | 2.27M | 4.43M | 1.51M | 1.19M | 1.71M |
Operating activities | ||||||||||
Net income | 5.08M | -22.98M | -11.51M | -12.72M | -10.96M | -5.69M | -4.23M | -3.34M | -1.56M | -2.97M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||||
Depreciation and amortization | 196K | 77K | 7K | 6K | 4K | 6K | 5.37K | 14.73K | 28.30K | 31.86K |
Stock-based compensation expense | 4.21M | 2.69M | 1.17M | 1.54M | 634K | 1.46M | 719.21K | 271.15K | 529.32K | 807.82K |
| Deferred income tax benefit | 4.21M | 2.69M | 1.17M | 1.54M | 634K | 1.46M | 719.21K | 271.15K | 529.32K | 807.82K |
| Changes in operating assets and liabilities: | ||||||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -2.22M | 2.06M | -816K | -612K | 470K | 475K | -146.23K | 0 | 0 | 0 |
Cash generated by operating activities | -10.29M | -21.18M | -12.44M | -14.65M | 4.65M | -4.06M | -3.39M | -2.30M | -1.66M | -1.41M |
Investing activities | ||||||||||
Purchases Of Investments | -190.91M | -53.82M | -39.38M | -26.57M | -31.05M | -55.75M | -5.84M | -475.35K | -1.70M | 0 |
Investments In Property Plant And Equipment | -254K | -375K | -82K | -5K | -9K | -14K | -6.37K | -2.12K | -2.18K | 0 |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | -42.61M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -73.03M | -23.76M | 4.62M | -7.00M | -16.01M | -13.08M | -4.56M | 1.76M | -1.71M | 901.24K |
Financing activities | ||||||||||
Common Stock Issued | 2.42M | 79.98M | 23.77M | 21.65M | 10.59M | 14.88M | 5.71M | 3.48M | 3.69M | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 49.55M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 51.97M | 102.89M | 23.78M | 22.65M | 12.04M | 16.64M | 5.82M | 3.48M | 3.69M | 0 |
Net Change In Cash | -31.40M | 57.94M | 15.96M | 1.02M | 694K | -510K | -2.15M | 2.91M | 313.72K | -517.22K |
Cash at end of period | 9.05M | 77.24M | 19.29M | 4.99M | 3.90M | 1.76M | 2.27M | 4.43M | 1.51M | 1.19M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |